We are live on ! Find out more
KCM

Kynam Capital Management Portfolio holdings

AUM $1.62B
1-Year Est. Return 138.67%
This Fund
S&P 500
This Quarter Est. Return
+0.71%
1 Year Est. Return
+138.67%
3 Year Est. Return
+268.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.3B
AUM Growth
+$341M
Cap. Flow
+$311M
Cap. Flow %
24.02%
Top 10 Hldgs %
81.93%
Holding
27
New
4
Increased
19
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
DVAX
Dynavax Technologies
DVAX
+$33.1M
2
VRDN icon
Viridian Therapeutics
VRDN
+$22.4M
3
CLDX icon
Celldex Therapeutics
CLDX
+$18.4M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$12.7M
5
COGT icon
Cogent Biosciences
COGT
+$5.77M

Top Sells

Rank Stock Value
1
LQDA icon
Liquidia Corp
LQDA
+$17.7M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$10.1M

Sector Composition

Rank Sector Weight
1 Healthcare 73.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGON icon
26
CG Oncology
CGON
$6.11B
$1.7M 0.13%
+53,911
New +$1.87M
CORT icon
27
PUT
Corcept Therapeutics
CORT
$10.2B
– –
-585,900
Closed -$14.8M
1
2

Similar funds

IPW
Invictus Private Wealth Denver, Colorado $1.62B AUM 22.63% 1-Year Est. Return
WIC
Woodmont Investment Counsel Nashville, Tennessee $1.62B AUM 18.92% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
TLFA
True Link Financial Advisors San Francisco, California $1.62B AUM 8.33% 1-Year Est. Return
KCM
Kathmere Capital Management Wayne, Pennsylvania $1.62B AUM 17.7% 1-Year Est. Return
PRA
Pine Ridge Advisers New York $1.62B AUM 16.97% 1-Year Est. Return
BW
Browning West Los Angeles, California $1.62B AUM 22.28% 1-Year Est. Return
CC
Covalis Capital London, United Kingdom $1.63B AUM 27.84% 1-Year Est. Return

Kynam Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, Kynam Capital Management held 27 positions worth $1.3B, up 36% from $955M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Kynam Capital Management deployed $311M of net new capital in Q2 2024, opening 4 new positions and adding to 19 existing holdings. Its largest new stake was CG Oncology: 53,911 shares worth $1.7M.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, down from 94% a quarter earlier.

On the sell side, the largest reduction was Liquidia Corp, an estimated $17.7M trimmed.

  • Kynam Capital Management's largest Q2 2024 buy was CG Oncology: 53,911 shares worth $1.7M.
  • Kynam Capital Management added most to Dynavax Technologies in Q2 2024, an estimated $33.1M increase.
  • Kynam Capital Management's biggest Q2 2024 reduction was Liquidia Corp, cutting an estimated $17.7M.
  • Kynam Capital Management's ten largest holdings make up 82% of its $1.3B portfolio in Q2 2024.
  • Kynam Capital Management opened 4 new positions and closed 1 in Q2 2024.
  • Kynam Capital Management's portfolio value rose 36% quarter-over-quarter to $1.3B.

Based on Kynam Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.